Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron dextran is an intravenous or intramuscular iron replacement medication used to treat iron deficiency anemia in patients for whom oral iron is ineffective or intolerable. It consists of a complex of ferric hydroxide and dextran, which is processed by the reticuloendothelial system to release elemental iron. This iron then binds to transferrin and is transported to the bone marrow for incorporation into hemoglobin. Iron dextran is notable for its ability to be administered as a total dose infusion (TDI), allowing for the correction of a patient's entire iron deficit in a single session. However, its use requires a test dose due to the risk of serious anaphylactoid reactions, which were historically more common with high molecular weight formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron dextran.